GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Electromed Inc (AMEX:ELMD) » Definitions » ROC %

Electromed (Electromed) ROC %

: 18.68% (As of Dec. 2023)
View and export this data going back to 2010. Start your Free Trial

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Electromed's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 18.68%.

As of today (2024-04-23), Electromed's WACC % is 5.22%. Electromed's ROC % is 11.15% (calculated using TTM income statement data). Electromed generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Electromed ROC % Historical Data

The historical data trend for Electromed's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Electromed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROC %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.98 19.27 10.18 8.46 9.58

Electromed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.31 12.93 11.86 1.16 18.68

Electromed ROC % Calculation

Electromed's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=4.008 * ( 1 - 22.52% )/( (30.059 + 34.777)/ 2 )
=3.1053984/32.418
=9.58 %

where

Electromed's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=9.052 * ( 1 - 29.04% )/( (34.534 + 34.246)/ 2 )
=6.4232992/34.39
=18.68 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Electromed  (AMEX:ELMD) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Electromed's WACC % is 5.22%. Electromed's ROC % is 11.15% (calculated using TTM income statement data). Electromed generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Electromed ROC % Related Terms

Thank you for viewing the detailed overview of Electromed's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Electromed (Electromed) Business Description

Traded in Other Exchanges
N/A
Address
500 Sixth Avenue NW, New Prague, MN, USA, 56071
Electromed Inc is a United States-based company that develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Executives
Andrew Summers director 601 JEFFERSON STREET, HOUSTON TX 77002
James L. Cunniff director, officer: CEO and President 500 SIXTH AVE NW, NEW PRAGUE MN 56071
Kathleen Skarvan officer: Chief Executive Officer 40 WEST HIGHLAND PARK DR NE, HUTCHINSON MN 55350
Bradley M. Nagel officer: Chief Financial Officer 500 SIXTH AVE NW, NEW PRAGUE MN 56071
Michelle C. Wirtz officer: Chief Financial Officer 500 SIXTH AVENUE NW,, NEW PRAGUE MN 56071
Christopher G. Holland officer: Chief Commercial Officer 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Joseph L. Galatowitsch director 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Kathleen A Tune director 60 SOUTH SIXTH STREET, SUITE 3620, MINNEAPOLIS MN 55402
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Stephen H. Craney director 25340 SANDPIPER LANE, WINONA MN 55987
Andrea M. Walsh director 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
George H. Winn director 27451 COUNTRY HOLLOWS LANE, NEW PRAGUE MN 56701
Michael Joseph Maccourt officer: Chief Financial Officer 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Gregory Fluet director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
John L Erb director C/O VASCULAR SOLUTIONS, INC., 6464 SYCAMORE COURT N., MINNEAPOLIS, MN 55369

Electromed (Electromed) Headlines

From GuruFocus

Sidoti Virtual Microcap Investor Conference

By ACCESSWIRE ACCESSWIRE 11-19-2020

Electromed Stock Appears To Be Significantly Overvalued

By GF Value GF Value 06-06-2021